TMB and MHC/antigen affinity of 12 patients were measured (Table S2) in a recent small clinical trial to examine effect of nivolumab in resectable lung cancer (ClinicalTrials.gov number, NCT02259621; the data reported in (11) were used in our simulations). This evidence concerns the gene HLA-C and lung carcinoma.